Skip to main content
Premium Trial:

Request an Annual Quote

Biametrics, MorphoSys to Expand High-Throughput Antibody Screening Collaboration


German technology firm Biametrics announced this week that it would expand its relationship with MorphoSys following a successful preliminary study that paired Biametrics' microarray technology with MorphoSys' therapeutic antibodies.

Florian Pröll, managing director at Tübingen-based Biametrics, said in a statement that the company "looks forward to expanding our collaboration in the field of biomolecular interaction analysis" with MorphoSys.

Biametrics and MorphoSys have been working together in the area of high-throughput antibody screening. According to Biametrics, in a pilot study, they used Biametrics' label-free B-screen microarray platform to characterize Fab fragment antigen interactions.

Biametrics recently launched B-screen as a research tool, and a handheld instrument called B-portable that relies on the same label-free technology is set for introduction later this year.

Markus Enzelberger, senior vice president and head of discovery alliances and technologies at MorphoSys, said in a statement that MorphoSys views B-screen as a "promising technology in the field of epitope mapping."

MorphoSys is based in Martinsried, Germany. The company maintains a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.